Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure: iNdications and outComEs (NCT04613921)
Liver Transplantation in Patients With CirrHosis and Severe Acute-on-Chronic Liver Failure (ACLF): iNdications and outComEs
🩺 Plain-English Summary (8th-Grade Level)
Management of ACLF is mainly supportive. The poor outcomes lead physicians to consider liver transplantation as an option, even if controversial. In sicker recipients, LT results in immediate survival, but poor medium-term survival rates in some studies. The scarcity of deceased donors obliges to maximize LT success. Alternative strategies, as living-donor LT, should be explored. LDLT has impressive results in Eastern centers, but it is restrained in Western countries, due to potential life-threatening complications in the donor.
Who can join: Review the eligibility criteria below.
Location: Cedars-Sinai Comprehensive Transplant Center — Los Angeles, California
Age range: 18 Years to 80 Years
🧪 Interventions in This Study
- Observational Protocol (OTHER)
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (106 Sites)
Showing the first 25 of 106 sites.
- Cedars-Sinai Comprehensive Transplant Center — Los Angeles, California
- University of Colorado — Aurora, Colorado
- Tampa General Hospital — Tampa, Florida
- Piedmont Healthcare — Atlanta, Georgia
- Northwestern Memorial Hospital — Chicago, Illinois
- The University of Chicago Medicine — Chicago, Illinois
- University of Maryland School of Medicine — Baltimore, Maryland
- Weill Cornell Medicine — New York, New York
- Icahn School of Medicine at Mount Sinai — New York, New York
- Montefiore Medical Center — New York, New York
- University of Cincinnati — Cincinnati, Ohio
- Cleveland Clinic — Cleveland, Ohio
- University of Pennsylvania — Philadelphia, Pennsylvania
- Vanderbilt University Medical Center — Nashville, Tennessee
- Baylor College of Medicine (Scott & White) — Dallas, Texas
- Michael E DeBakey VA Medical Center — Houston, Texas
- Baylor St. Luke's Medical Centre — Houston, Texas
- University of Utah Health — Salt Lake City, Utah
- Austral University Hospital — Buenos Aires,
- Hospital Alemán — Buenos Aires,
- Italian Hospital in Buenos Aires — Buenos Aires,
- Austin Hospital — Heidelberg,
- Sir Charles Gairdner Hospital — Nedlands,
- Royal Prince Alfred Hospital — Sydney,
- Medical University of Vienna, Department of Transplant Surgery — Vienna,
📞 Contact the Study Coordinator
Phone: 34 93 227 1400
Email: anna.bosch@efclif.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Liver Diseases
- Coronavirus Disease 2019 (Covid-19) Impact on Alcohol-related Liver Disease Patient Outcomes, Care and Alcohol Use — San Francisco, California
- Liver Cancer Prevention Randomized Control Trial — Houston, Texas
- RESTORE Declined Livers Study — St Louis, Missouri
- Liver Micro Flow - MRI — Madison, Wisconsin
- The Microbiota Augmentation to Reestablish Commensal Organisms (MARCO) Trial — Chicago, Illinois
- MAsS Scan as a Predictor of Morbidity and Mortality in Patients With Liver Disease — Chicago, Illinois
Explore by condition: All Liver Diseases clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.